These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36759506)

  • 1. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
    Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
    PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
    Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
    EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
    Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
    PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells.
    Yost KE; Clatterbuck Soper SF; Walker RL; Pineda MA; Zhu YJ; Ester CD; Showman S; Roschke AV; Waterfall JJ; Meltzer PS
    Sci Rep; 2019 Mar; 9(1):4544. PubMed ID: 30872698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibition.
    Gaela VM; Hsia HY; Joseph NA; Tzeng WY; Ting PC; Shen YL; Tsai CT; Boudier T; Chen LY
    Nucleic Acids Res; 2024 Jun; 52(11):6472-6489. PubMed ID: 38752489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
    Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
    Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRX modulates the escape from a telomere crisis.
    Geiller HEB; Harvey A; Jones RE; Grimstead JW; Cleal K; Hendrickson EA; Baird DM
    PLoS Genet; 2022 Nov; 18(11):e1010485. PubMed ID: 36350851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
    Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
    PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
    Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.